71 related articles for article (PubMed ID: 2252659)
1. Basic studies on a new material for inducing antitumor immune cells.
Yamazaki Z; Hiraishi M; Kanai F; Takahama T; Idezuki Y; Yasuda K; Ohsawa Y; Sugawara T; Watanabe H; Inagaki K
ASAIO Trans; 1990; 36(3):M209-11. PubMed ID: 2252659
[TBL] [Abstract][Full Text] [Related]
2. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
Kimoto Y
Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
[TBL] [Abstract][Full Text] [Related]
3. Lectin-activated killer cells rapidly induced by pokeweed mitogen conjugated beads and their in vivo antitumor effects.
Ohno S; Tanaka N; Hizuta A; Miyagi K; Orita K
Int J Immunopharmacol; 1994 Sep; 16(9):761-8. PubMed ID: 7806434
[TBL] [Abstract][Full Text] [Related]
4. Polyethylene glycol-modified pokeweed mitogen (PWM) as a potential non-immunogenic stimulator of lymphokine-activated killer cells.
Ueno T; Kodera Y; Kimoto Y; Sakurai K; Hiroto M; Matsushima A; Nishimura H; Takai S; Inada Y
J Biomater Sci Polym Ed; 1996; 7(9):753-8. PubMed ID: 8773879
[TBL] [Abstract][Full Text] [Related]
5. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
[TBL] [Abstract][Full Text] [Related]
6. Enhancing effect of pokeweed mitogen on the proliferation and the cytotoxicity of lymphokine-activated killer cells.
Kimoto Y; Tanaka T; Fujiwara A; Fujita M; Taguchi T
Jpn J Cancer Res; 1992 Jun; 83(6):631-7. PubMed ID: 1379578
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
[TBL] [Abstract][Full Text] [Related]
8. Human lymphokine-activated killer cells suppress pokeweed mitogen-induced immunoglobulin synthesis.
Suzuki H; Yamashita N; Maruyama M; Yoshikawa T; Yano S
Clin Exp Immunol; 1989 Dec; 78(3):406-11. PubMed ID: 2532992
[TBL] [Abstract][Full Text] [Related]
9. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
10. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
Kimoto Y; Tanaka T; Tanji Y; Fujiwara A; Taguchi T
Biotherapy; 1994; 8(1):41-50. PubMed ID: 7547080
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
Teichmann JV; Ludwig WD; Thiel E
Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the antitumor activity of human IL-4 by in vitro and in vivo assays.
Wang T; Chen W
Chin Med Sci J; 1994 Dec; 9(4):248-54. PubMed ID: 7718866
[TBL] [Abstract][Full Text] [Related]
13. [Apoptosis of tumor cells in lectin-dependent lymphokine-activated killer cell-mediated cytotoxicity].
Dong H; Xing R; Guo L
Zhonghua Zhong Liu Za Zhi; 1995 Jul; 17(4):245-8. PubMed ID: 7587887
[TBL] [Abstract][Full Text] [Related]
14. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy.
Hong WS; Kim CM; Lee JO; Kang TW; Yun TK; Kim CY
Jpn J Clin Oncol; 1990 Mar; 20(1):87-93. PubMed ID: 2108272
[TBL] [Abstract][Full Text] [Related]
15. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
16. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
Holladay FP; Heitz T; Wood GW
J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
Nio Y; Zighelboim J; Berek JS; Bonavida B
Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
[TBL] [Abstract][Full Text] [Related]
19. On-line cell manipulation for cancer treatment.
Tani T; Numa K; Abe H; Yokota T; Kodama M
Artif Organs; 1992 Jun; 16(3):243-7. PubMed ID: 10078253
[TBL] [Abstract][Full Text] [Related]
20. Lymphokine-activated killer cells can kill target cells not only by early killing but also by late killing, and the late killing level against autotumor cell line.
Komatsu F; Ishiguro K
Oncol Res; 2003; 13(4):235-41. PubMed ID: 12659424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
